Uterine Papillary Serous Carcinoma: Evaluation of Long-Term Survival in Surgically Staged Patients

Grice, Jeffrey E.; Ek, Marit; Greer, Benjamin E.; Koh, Wui-Jin; Muntz, Howard G.; Cain, Joanna M.; Tamimi, Hisham K.; Stelzer, K.; Figge, David C.; Goff, Barbara A.

doi:10.1006/gyno.1998.4956

Cited by 141 publications

(65 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adjuvant therapy is highly individualized. [91][92][93][94][95] Adjuvant therapy recommendations for stage IA include observation and/or chemotherapy, or tumordirected RT. 96 Recommendations for stage 1B to II include chemotherapy with or without tumor-directed RT, or whole abdominopelvic RT with or without vaginal brachytherapy (category 3).…”

Section: Treatment Of Relapsed or Metastatic Diseasementioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

Self Cite

View full text Add to dashboard Cite

Section: Treatment Of Relapsed or Metastatic Diseasementioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

Self Cite

View full text Add to dashboard Cite

“…Retrospective studies looking at women with USC suggest that inadequate staging may have a negative impact on survival and outcome. 14,[17][18][19] In one report by Thomas et al, 14 a trend towards a lower recurrence rate was found in women with USC who underwent systemic lymphadenectomy. However, it has been questioned whether lymphadenectomy can be safely omitted in USC as the majority of women will receive adjuvant therapy regardless of their surgical stage.…”

Section: Introductionmentioning

confidence: 95%

“…Hence, many authors recommend comprehensive surgical staging in women diagnosed with USC regardless of tumour size and depth of myometrial invasion. 9,[14][15][16][17][18][19] Controversies continue to exist regarding the survival impact of lymphadenectomy in endometrial cancer in general. A recent randomised prospective trial showed no survival benefit from pelvic lymphadenectomy in endometrial carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of lymphadenectomy in uterine serous cancer

Mahdi

Kumar

Al-Wahab

et al. 2012

BJOG

View full text Add to dashboard Cite

Objective To estimate the survival impact of lymphadenectomy in women diagnosed with uterine serous cancer.Design Women with a diagnosis of uterine serous cancer were identified from the Surveillance, Epidemiology and End Results Program (SEER) from 1988 to 2007. Only surgically treated women were included.Setting The Surveillance, Epidemiology and End Results Program database provided data from 17 registries.Population The study population comprised 4178 women.Methods Statistical analyses using Student's t-test, Kaplan-Meier survival methods and Cox proportional hazards regression were performed.Main outcome measure Overall survival.Results Three thousand, one hundred and ninety-four (67.7%) women underwent lymphadenectomy. Older women ( ‡65 years) and Caucasian women (relative to Asian) were less likely to have lymphadenectomy (P < 0.001). The prevalence of nodal metastasis in women having lymphadenectomy was 32%. Of the 1997 women who had disease grossly confined to the uterus and underwent lymphadenectomy, 387 (19%) were found to have nodal metastasis. Lymphadenectomy was associated with improved survival; women who underwent lymphadenectomy were 41% (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.54-0.64; P < 0.001) less likely to die than women who did not have the procedure. Moreover, more extensive lymphadenectomy correlated positively with survival. Compared with women with 1-10 nodes removed, those with more extensive lymphadenectomy (>10 nodes removed) were 26% (HR, 0.74; 95% CI, 0.67-0.83; P < 0.001) less likely to die. The impact of the extent of lymphadenectomy on survival was significant in both node-negative and node-positive women.Conclusion Age and race influenced the prevalence of lymphadenectomy in our cohort. This study suggests that the extent of lymphadenectomy is associated with significant improvement in survival of women with uterine serous cancer.

show abstract

“…Endometrial adenocarcinomas are classified into two predominant histologic groups, endometrioid carcinomas, which account for 80% of endometrial adenocarcinomas, and the nonendometrioid types (12). Nonendometrioid endometrial carcinomas, including uterine papillary serous carcinomas and clear cell carcinomas, are infrequent; however they are high-grade, aggressive tumors with a poor clinical outcome (13)(14)(15). Uterine papillary serous carcinomas and clear cell carcinomas are not estrogen-responsive and arise from precancerous lesions that develop in atrophic endometrium (16).…”

Section: Introductionmentioning

confidence: 99%

Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer

Woo

Alkushi

Verhage

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Lesions in the endometrium are difficult to differentially diagnose. The present study examined whether oviduct-specific glycoprotein is differentially expressed in normal, hyperplastic, and malignant endometrium.Experimental Design: The expression of oviduct-specific glycoprotein was characterized by immunohistochemical methods with whole sections of endometrium from 90 women. An endometrial cancer tissue microarray with 200 cases of endometrial cancer was also assessed for oviductspecific glycoprotein, estrogen receptor, and PTEN expression.Results: In normal endometrium, there was focal oviduct-specific glycoprotein expression in the basalis layer, where the stem cells reside, in 10 of 15 cases. On average, atypical hyperplastic endometria stained more intensely than hyperplastic endometria (P ‫؍‬ 0.017), whereas the percentage of positively stained cells was not significantly different. The mean staining indices (intensity ؋ percentage of positive cells score) for hyperplasia and atypical hyperplastic were 4.7 and 5.5 and were significantly higher than staining indices seen in normal cycling endometria or welldifferentiated endometrioid endometrial carcinomas (P < 0.0001 and P < 0.001, respectively). The endometrial cancer tissue microarray showed that of 139 endometrioid endometrial carcinomas, 11 cases were strongly oviduct-specific glycoprotein positive, whereas the other 128 cases were negative or weakly positive. Analysis of Kaplan-Meier curves with log-rank statistics showed a trend toward significance, with strong oviduct-specific glycoprotein staining serving as a predictor of good prognosis (P ‫؍‬ 0.1). There was a significant positive correlation between oviduct-specific glycoprotein staining and loss of PTEN in the cases of endometrial cancer (P ‫؍‬ 0.004).Conclusions: Oviduct-specific glycoprotein may be a useful diagnostic adjunct to more accurately classify premalignant and early malignant change in the endometrium, improving on the current irreproducible histologic classification system.

show abstract

Uterine Papillary Serous Carcinoma: Evaluation of Long-Term Survival in Surgically Staged Patients

Cited by 141 publications

References 27 publications

Uterine Neoplasms

Uterine Neoplasms

Prognostic impact of lymphadenectomy in uterine serous cancer

Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer

Contact Info

Product

Resources

About